Jeremy S. Abramson

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema et al. · New England Journal of Medicine · 2018 · 952 citations · Full text

Medicine, Immunology, Oncology +10

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Adam M. Petrich, Mitul Gandhi, Borko Jovanovic et al. · Blood · 2014 · 466 citations

Medicine, Oncology, Hematologic Oncology +9

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

Nancy L. Bartlett, Wyndham H. Wilson, Sin‐Ho Jung et al. · Journal of Clinical Oncology · 2019 · 423 citations

Medicine, Oncology, Chemotherapy +10

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason et al. · Blood · 2022 · 368 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma

Matija Snuderl, Olga Kolman, Yi‐Bin Chen et al. · The American Journal of Surgical Pathology · 2010 · 355 citations · Full text

Medicine, Hematology, Pathology +17